Jove
Visualize
Contact Us

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Tumor Progression02:07

Tumor Progression

7.7K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Digitized Health Opens RWE Floodgates. Can Artificial Intelligence Harness the Power?

Managed care (Langhorne, Pa.)·2019
Same authorSame journal

To Be Continued:The Search for a Cure for HIV.

Managed care (Langhorne, Pa.)·2019
Same author

Show Us (the U.S.) the Savings.

Managed care (Langhorne, Pa.)·2019
Same author

Why Biosimilars Can Never Be Identical To Originators-and Why They Don't Need To Be.

Managed care (Langhorne, Pa.)·2019
Same author

Why marijuana is headed for the mainstream.

Managed care (Langhorne, Pa.)·2019
Same author

Rumble Over Drug Rebates As Pharma, Payers Duke It Out.

Managed care (Langhorne, Pa.)·2018
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Mar 8, 2026

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.6K

Finally, Attention Switches To Progressive Multiple Sclerosis.

Thomas Reinke

    Managed Care (Langhorne, Pa.)
    |January 26, 2017
    PubMed
    Summary

    New treatments offer hope for multiple sclerosis (MS) patients beyond the relapsing-remitting form. Ocrelizumab targets and eliminates CD20-positive B cells, addressing a different aspect of MS pathology.

    Area of Science:

    • Immunology
    • Neurology
    • Pharmacology

    Background:

    • Multiple Sclerosis (MS) treatments have primarily focused on the relapsing-remitting form.
    • There is a significant unmet need for therapies targeting other MS subtypes.
    • Aberrant B cell populations are implicated in MS pathogenesis.

    Purpose of the Study:

    • To investigate the efficacy of ocrelizumab in a different form of MS.
    • To evaluate the mechanism of action of ocrelizumab targeting CD20-positive B cells.

    Main Methods:

    • Ocrelizumab targets CD20-positive B cells.
    • The drug eliminates these cells from the bloodstream.
    • This approach addresses a specific B cell population implicated in MS.

    More Related Videos

    The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
    11:35

    The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

    Published on: June 30, 2014

    58.8K
    Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
    08:51

    Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

    Published on: February 19, 2021

    10.0K

    Related Experiment Videos

    Last Updated: Mar 8, 2026

    Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
    08:11

    Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

    Published on: November 14, 2016

    11.6K
    The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
    11:35

    The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

    Published on: June 30, 2014

    58.8K
    Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
    08:51

    Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

    Published on: February 19, 2021

    10.0K

    Main Results:

    • Ocrelizumab demonstrates a mechanism to address MS beyond relapsing-remitting forms.
    • The treatment targets and depletes CD20-positive B cells.
    • This offers a potential therapeutic avenue for specific MS patient groups.

    Conclusions:

    • Ocrelizumab provides a new therapeutic strategy for MS.
    • Targeting CD20-positive B cells offers hope for patients with MS subtypes.
    • Further research is warranted to explore its full potential.